Similar articles

• Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.

  Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres AC, Ducerf C, Mabrut JY, Rode A, Levrero M, Combet C, Merle P, Zoulim F. Virlogeux V, et al. Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25. Liver Int. 2017. PMID: 28423231
• Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.

  Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, Serio I, Verrucchi G, Bacchi Reggiani ML, Colli A, Marasco G, Colecchia A, Festi D. Ravaioli F, et al. Dig Liver Dis. 2018 Jun;50(6):573-579. doi: 10.1016/j.dld.2018.02.010. Epub 2018 Feb 27. Dig Liver Dis. 2018. PMID: 29567413
• The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?

  Blanco JR, Rivero-Juárez A. Blanco JR, et al. Expert Rev Anti Infect Ther. 2016 Nov;14(11):993-996. doi: 10.1080/14787210.2016.1243466. Expert Rev Anti Infect Ther. 2016. PMID: 27686837 No abstract available.
• Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma.

  Hsu YC, Wu CY, Lin JT. Hsu YC, et al. Semin Oncol. 2015 Apr;42(2):329-38. doi: 10.1053/j.seminoncol.2014.12.023. Epub 2014 Dec 31. Semin Oncol. 2015. PMID: 25843737 Review.
• American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.

  Jacobson IM, Lim JK, Fried MW. Jacobson IM, et al. Gastroenterology. 2017 May;152(6):1578-1587. doi: 10.1053/j.gastro.2017.03.018. Epub 2017 Mar 23. Gastroenterology. 2017. PMID: 28344022 Review.